Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein

Urticaria is a common cutaneous adverse event from coronavirus disease 2019 vaccination. Previous studies hypothesized that excipients as polyethylene glycol in BNT162b2 vaccine and polysorbate in ChAdOx1 nCoV-19 vaccine are allergens. A 28-year-old woman had urticaria after a booster vaccination wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Triwatcharikorn, Jidapa, Klaewsongkram, Jettanong, Rerknimitr, Pawinee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2022
Materias:
Hypothesis & Experience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353207/
https://www.ncbi.nlm.nih.gov/pubmed/35966159
http://dx.doi.org/10.5415/apallergy.2022.12.e27
_version_ 1784762824763899904
author Triwatcharikorn, Jidapa
Klaewsongkram, Jettanong
Rerknimitr, Pawinee
author_facet Triwatcharikorn, Jidapa
Klaewsongkram, Jettanong
Rerknimitr, Pawinee
author_sort Triwatcharikorn, Jidapa
collection PubMed
description Urticaria is a common cutaneous adverse event from coronavirus disease 2019 vaccination. Previous studies hypothesized that excipients as polyethylene glycol in BNT162b2 vaccine and polysorbate in ChAdOx1 nCoV-19 vaccine are allergens. A 28-year-old woman had urticaria after a booster vaccination with BNT162b2 at the site of previous intradermal injection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein. This reaction emphasized that delayed urticaria may not be an allergic reaction to excipient but rather to the immunogen as such as SARS-CoV-2 spike protein.
format Online
Article
Text
id pubmed-9353207
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Asia Pacific Association of Allergy, Asthma and Clinical Immunology
record_format MEDLINE/PubMed
spelling pubmed-93532072022-08-12 Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein Triwatcharikorn, Jidapa Klaewsongkram, Jettanong Rerknimitr, Pawinee Asia Pac Allergy Hypothesis & Experience Urticaria is a common cutaneous adverse event from coronavirus disease 2019 vaccination. Previous studies hypothesized that excipients as polyethylene glycol in BNT162b2 vaccine and polysorbate in ChAdOx1 nCoV-19 vaccine are allergens. A 28-year-old woman had urticaria after a booster vaccination with BNT162b2 at the site of previous intradermal injection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein. This reaction emphasized that delayed urticaria may not be an allergic reaction to excipient but rather to the immunogen as such as SARS-CoV-2 spike protein. Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2022-07-18 /pmc/articles/PMC9353207/ /pubmed/35966159 http://dx.doi.org/10.5415/apallergy.2022.12.e27 Text en Copyright © 2022. Asia Pacific Association of Allergy, Asthma and Clinical Immunology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Hypothesis & Experience
Triwatcharikorn, Jidapa
Klaewsongkram, Jettanong
Rerknimitr, Pawinee
Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein
title Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein
title_full Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein
title_fullStr Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein
title_full_unstemmed Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein
title_short Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein
title_sort delayed urticaria after bnt162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein
topic Hypothesis & Experience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353207/
https://www.ncbi.nlm.nih.gov/pubmed/35966159
http://dx.doi.org/10.5415/apallergy.2022.12.e27
work_keys_str_mv AT triwatcharikornjidapa delayedurticariaafterbnt162b2boostervaccinationatpreviousintradermaltestsitewithsevereacuterespiratorysyndromecoronavirus2spikeprotein
AT klaewsongkramjettanong delayedurticariaafterbnt162b2boostervaccinationatpreviousintradermaltestsitewithsevereacuterespiratorysyndromecoronavirus2spikeprotein
AT rerknimitrpawinee delayedurticariaafterbnt162b2boostervaccinationatpreviousintradermaltestsitewithsevereacuterespiratorysyndromecoronavirus2spikeprotein

Ejemplares similares